exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089246 RNA Name: hsa-miR-624-3p RNA Type: miRNA Chromosome: chr14 Starnd: - Coordinate: Start Site(bp): 31014669 End Site(bp): 31014689 External Links: hsa-miR-624-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CBL chr11 119206298 119313926 + GPCPD1 chr20 5544439 5611006 - MDK chr11 46380756 46383837 + PTPA chr9 129110950 129148946 + SOBP chr6 107490106 107661306 + VANGL1 chr1 115641970 115698224 + WSB2 chr12 118032694 118062430 - ZBTB5 chr9 37438102 37465450 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000095 chr1 95609446 95616975 + hsa_circ_0000698 chr16 47531309 47549512 + hsa_circ_0000552 chr14 71880664 71948928 + hsa_circ_0001376 chr3 194169185 194175121 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005034.3 chr2 75697583 75697996 + AC010327.5 chr19 55216660 55221616 + AC016876.2 chr17 7581964 7584086 - AL162171.3 chr14 88589231 88592408 + ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - DHRS4-AS1 chr14 23938219 24052555 - MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + SNHG1 chr11 62851984 62855953 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.